Preclinical News and Research

RSS

Ketone body β-hydroxybutyrate restores protein balance and targets Alzheimer’s-linked aggregates

Scientists identify β-hydroxybutyrate as a key regulator of protein solubility, offering a novel pathway to combat neurodegeneration in aging and Alzheimer’s disease.

4 Dec 2024

New discovery offers hope for treating aggressive adenoid cystic carcinoma

A new editorial was published in Oncotarget's Volume 15 on November 22, 2024, entitled "B7-H4: A potential therapeutic target in adenoid cystic carcinoma."

4 Dec 2024

Study reveals non-invasive technique for early detection of sepsis

Clinicians lack methods for early detection of sepsis, a dysregulated response to infection that can result in life-threatening organ failure if treatment is delayed.

4 Dec 2024

Behavioral chaos in Alzheimer’s disease mice decoded by machine learning

Researchers use machine learning to identify behavioral disruptions in Alzheimer’s disease mouse models, highlighting a potential therapeutic target in fibrinogen-microglia interactions.

3 Dec 2024

Serum protein panel test can help identify cardiomyopathy risk in childhood cancer survivors

Early disease detection is beneficial for securing the best possible outcomes for patients. But finding noninvasive, effective ways to predict disease risk is a tremendous challenge.

3 Dec 2024

Study cracks the cold case of immunotherapy resistance

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.

3 Dec 2024

New immune therapy improves survival and reduces tumor burden in glioblastoma

The Wistar Institute's David B. Weiner, Ph.D. - Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research - and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma.

3 Dec 2024

Overcoming challenges in developing cell therapies for heart disease

Pathways to new treatments for heart failure take time - as long as four decades for two now accepted therapies. So, new attempts to repair scar tissue in infarcted hearts using cells or cell products need more time to develop clinical therapies that can reduce risk of death from heart failure after a heart attack.

3 Dec 2024

Study reveals how stem cells sense and respond to their environment

A new study from The Hospital for Sick Children (SickKids) and Institut Curie reveals how stem cells sense and respond to their environment, with implications for inflammatory bowel disease and colorectal cancer.

2 Dec 2024

Hypothalamic DBS therapy improves recovery of lower limb movements after spinal cord injury

Researchers at EPFL and Lausanne University Hospital (CHUV), led by professors Grégoire Courtine and Jocelyne Bloch, have achieved a major milestone in the treatment of spinal cord injuries (SCI).

2 Dec 2024

Boosting endocannabinoids could reduce opioid addiction risk

Increasing the levels of chemicals naturally produced in the body called endocannabinoids may thwart the highly addictive nature of opioids such as morphine and oxycodone while maintaining the drugs' ability to relieve pain, according to Weill Cornell Medicine investigators working with researchers from The Center for Youth Mental Health at NewYork-Presbyterian.

2 Dec 2024

Natural polyphenol boosts mitochondrial function and muscle performance during aging

Oleuropein enhances mitochondrial calcium uptake, reversing age-related declines in muscle function and energy metabolism, with promising clinical potential.

2 Dec 2024

Novel mRNA-based therapy offers hope for patients with proliferative vitreoretinopathy

A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a retinal detachment repair or traumatic injury to the eye.

27 Nov 2024

Fungus found in the mouse stomach may hold a key to fungal evolution in the gut

A fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators.

27 Nov 2024

Machine learning tool detects early signs of Alzheimer's in mice

Subtle signs of Alzheimer's disease can emerge decades before a diagnosis - often in the form of irregular behaviors that reflect very early stages of brain dysfunction.

26 Nov 2024

Metrion Biosciences appoints Lee Patterson as CEO

Metrion Biosciences (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets.

From Metrion Biosciences Limited 26 Nov 2024

Study unlocks the secrets of beta cell regeneration

Prof. Heiko Lickert is the director of the Institute of Diabetes and Regeneration Research at Helmholtz Munich, professor at the Technical University of Munich (TUM), and member of the German Center for Diabetes Research (DZD).

26 Nov 2024

New initiative aims to explore diet’s role in lupus care

Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance (LRA), today announced a pioneering funding mechanism to address one of the most common questions about lupus clinical care and management.

22 Nov 2024

Penn engineers cook up a new way for safer, more effective mRNA therapies

Penn Engineers have cooked up a new way to improve mRNA delivery, developing an optimal "recipe" for ionizable lipids - key ingredients in lipid nanoparticles (LNPs), the molecules behind the COVID-19 vaccines and other innovative therapies.

22 Nov 2024

AI-designed drug ISM5939 granted IND clearance for cancer clinical trials

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors.

22 Nov 2024